From GlobeNewswire: 2025-05-31 16:30:00

In a Phase 2 trial, Actuate Therapeutics’ elraglusib/GnP combination therapy showed a significant increase in median overall survival for previously untreated patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). The risk of death was reduced by 37%, with a 12-month survival rate of 44.1%. The company plans to engage with the FDA for product registration. A KOL event will be held today to discuss the trial results. The study also showed improved overall response rates and progression-free survival with a manageable safety profile. The therapy works by inhibiting GSK-3β and enhancing chemotherapy activity.



Read more at GlobeNewswire: Actuate Therapeutics Presents Topline Elraglusib Phase 2